Business Description
Kiniksa Pharmaceuticals International plc is a London-based company focused on bringing new treatments to patients with rare and chronic inflammatory conditions. Its main product, ARCALYST, is approved for recurrent pericarditis, a painful and recurring inflammation of the lining around the heart. The company is also advancing two additional drug candidates through early and mid-stage clinical development, both targeting similar inflammatory diseases. Originally founded in 2015, Kiniksa operates across the United States, the United Kingdom, and other international markets.
